White Paper: Using AI to Discover Targets and Mechanism of Action from High-Content Imaging Screen

BioSymetrics is applying artificial intelligence (AI) and machine learning capabilities to the discovery and development of new drugs using a proprietary Contingent AI™ platform. 

BioSymetrics White Paper: Using Contingent-AI to Discovery Targets and Mechanism of Action from High-Content Imaging Screen

BioSymetrics White Paper: Using Contingent-AI to Discovery Targets and Mechanism of Action from High-Content Imaging Screen

 
 
Previous

Poster Presentation - MIT AI in Drug Discovery 2020
Next

Paper - Using iterative Machine Learning (Contingent-AI) in a clinical setting